The FDA granted fast-track designation to Eli Lilly and Co. and Incyte's baricitinib, which is being developed to treat patients with systemic lupus erythematosus.
Lilly, Incyte's lupus candidate nabs FDA fast-track status
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.